Claims for Patent: 7,700,299

Summary for Patent: 7,700,299

Title:	Method for predicting the response to a treatment
Abstract:	The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.
Inventor(s):	Moecks; Joachim (Mannheim, DE), Strauss; Andreas (Penzberg, DE), Zugmaier; Gerhard (Stuttgart, DE)
Assignee:	Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:	11/438,033
Patent Claims:	1. A method of predicting the response of a metastatic breast cancer patient to treatment with pertuzumab comprising the steps of: (a) determining the amount of each of the following biomarkers in a biological sample from a metastatic breast cancer patient that has been treated with pertuzumab: (1) the amino acid sequence of SEQ ID NO: 1; (2) the amino acid sequence of SEQ ID NO: 2; (3) the amino acid sequence of SEQ ID NO: 3; and (4) the amino acid sequence consisting of residues 22 to 645 of SEQ ID NO: 4; (b) determining whether the amount assessed in step (a) is above or below a quantity that is associated with an increased or decreased clinical benefit to a metastatic breast cancer patient; and (c) predicting the response to the treatment with pertuzumab in the patient by evaluating the results of step (b). 2. The method of claim 1 wherein said biological sample is obtained from blood serum and the quantity of the amino acid sequence of SEQ ID NO: 3 that is associated with an increased clinical benefit to a metastatic breast cancer patient is between 2.0-10.0 pg/ml. 3. The method of claim 1 wherein said biological sample is obtained from blood serum and the quantity of the amino acid sequence consisting of residues 22 to 645 of SEQ ID NO: 4 that is associated with an increased clinical benefit to a metastatic breast cancer patient is between 12-22 ng/ml. 4. The method of claim 1 wherein said biological sample is obtained from blood serum and the quantity of the amino acid sequence of SEQ ID NO: 1 that is associated with an increased clinical benefit to a metastatic breast cancer patient is between 6-15 pg/ml. 5. The method of claim 1 wherein said biological sample is obtained from blood serum and the quantity of the amino acid sequence of SEQ ID NO: 2 that is associated with an increased clinical benefit to a metastatic breast cancer patient is between 100-250 pg/ml. 6. The method of claim 1 wherein said biological sample is obtained from blood serum and the quantity of said amino acid sequence consisting of residues 22 to 645 of SEQ ID NO: 4 that is associated with an increased clinical benefit to a patient is about 18 ng/ml and the quantity of said amino acid sequence of SEQ ID NO: 3 that is associated with an increased clinical benefit to a patient is about 3.5 pg/ml. 7. The method according to claim 1 wherein the quantity in step (b) of claim 1 is determined by: (1) determining the amount of said biomarkers in a plurality of biological samples from patients before treatment with pertuzumab, (2) treating the patients with pertuzumab, (3) determining the clinical benefit of each patient; and (4) correlating the clinical benefit of the patients treated with the pertuzumab to the amount of said biomarkers. 8. The method according to claim 1, wherein the amount of each biomarker is determined by using a reagent which specifically binds with said biomarker protein. 9. The method of claim 8, wherein the reagent is an antibody. 10. The method according to claim 1 wherein said biological sample is obtained from blood serum and the quantity of said amino acid sequence consisting of residues 22 to 645 of SEQ ID NO: 4 that is associated with an increased clinical benefit to a metastatic breast cancer patient is about 18 ng/ml. 11. A method of predicting the response of a metastatic breast cancer patient to treatment with pertuzumab comprising the steps of: (a) determining the amount of each of the following biomarkers in a biological sample from a metastatic breast cancer patient that has been treated with pertuzumab: (1) the amino acid sequence of SEQ ID NO: 1; (2) the amino acid sequence of SEQ ID NO: 2; (3) the amino acid sequence of SEQ ID NO: 3; and (4) the amino acid sequence consisting of residues 22 to 645 of SEQ ID NO: 4; (b) determining whether the amount assessed in step (a) of SEQ ID NO: 1 is between 6 and 15 pg/ml, of SEQ ID NO: 2 is between 100 and 250 pg/ml, of SEQ ID NO: 3 is between 2.0 and 10.0 pg/ml, and of the amino acid sequence consisting of residues 22 to 645 SEQ ID NO: 4 is between 12 and 22 ng/ml; (c) predicting the response to the treatment with pertuzumab in the patient by evaluating the results of step (b).

Details for Patent 7,700,299

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2025-08-12